Pharmaceutical Patent
Pioneering Solutions in Drug Development.
Invention Patents
Innovative preparation methods for APIs and intermediates.
Utility Model Patents
Innovation and creation of pharmaceutical facilities and equipment.
Autonomous Patent Authorization
Independent ownership and control of patent rights.
Development of New Product
Implementation and improvement of production processes and methods.
Product Process Improvement
Improvement of existing product processes to meet more detailed needs.
Innovation Project Research
Host and conduct provincial-level technology innovation project research.
Patents in Pharmaceutical Industry
“We are committed to protecting our innovations through pharmaceutical
patents while ensuring that they benefit a wider patient population.”
Patents are the Cornerstone of Innovation in the Pharmaceutical Industry
We are well aware that every patent is a commitment to human health and an exploration of future possibilities. We are proud to announce that we have successfully transformed 27 invention patents and 40 new patents, which have not only promoted the progress of medical technology, but also benefited patients.
What did we do?
What's News
Latest news at Tianming
Core Considerations in Designing Complex Pharmaceutical Intermediate Synthesis Routes: Practical Notes from the Field
This article shares real-world insights from two decades of pharmaceutical process development, focusing on how synthesis route design for complex intermediates directly impacts cost, scalability, impurity control, and regulatory compliance.
Cardiovascular Drug Intermediates: In-Depth Analysis of Key Compounds and Market Demand
Explore key pharmaceutical intermediates for cardiovascular drugs, manufacturing requirements, and global market demand supported by regulatory and industry data.
Crystallization & Solid Form Challenges for Intermediates
Crystallization and solid-form control are critical to intermediate quality, scalability, and downstream API performance. This article explores common solid-state challenges, scale-up risks, and why early crystallization expertise at the intermediate stage reduces development and regulatory uncertainty.